《美股業績》莫德納(MRNA.US)首季純利按年升兩倍 料全年新冠疫苗銷售210億美元
生產新冠疫苗的美國生物醫藥企業莫德納(Moderna)(MRNA.US)公佈首季業績。季度淨利潤36.57億元,按年升約兩倍。每股季度攤薄純利8.58美元。季度收入60.66億美元,按年升2.13倍。當中新冠疫苗收入佔59億美元。
公司預期下半年疫苗銷售將優於上半年,料新冠將變爲季節性,並在秋季將須接種加強劑,尤其爲高危人士,公司正研發針對Omicron變種的疫苗。公司預測全年疫苗銷售210億美元,但若全球疫苗分享計劃未確定中低收入國家需求,疫苗銷售或會較少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.